Streetbeat News

Revenues

NVAX

Novavax has revised its FY23 revenue guidance to $900M-$1.1B, down from the previous estimate of $1.3B-$1.5B. The company also expects Q1 FY24 revenue of $300M. The updated guidance reflects the full delivery timing and revenue recognition of sales associated with the 2023-2024 vaccination season. The company expects some revenue recognition to extend into Q1 2024 due to a delayed start and longer season in the U.S.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:07 pm

IHRT

iHeartMedia has provided a Q4 revenue growth outlook, expecting a high-single digit decline in consolidated revenue. The company also expects Q4 consolidated adjusted EBITDA to be between $205 million and $215 million. iHeartMedia remains committed to a long-term target of approximately 4x net debt to adjusted EBITDA.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:06 pm

IHRT

iHeartMedia reported Q3 2023 results with Digital Audio Group Revenue of $267 million, up 5% YoY, and Podcast Revenue of $103 million, up 13% YoY. However, Multiplatform Group Revenue was $626 million, down 5% YoY. The company's Digital Audio Group Adjusted EBITDA margin was 35.1%, while the Multiplatform Group Adjusted EBITDA margin was 25.9%.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:03 pm

PRTH

Priority Technology has revised its 2023 revenue forecast downwards from $765M-$780M to $755M-$765M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:38 pm

SGHC

Super Group's Q3 revenue has increased by 16% to €356.9M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:31 pm

SHCR

Sharecare has projected its Q4 revenue to be between $111M-$113M. The company also maintains its 2023 revenue forecast of $452.5M-$460M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:28 pm

LASE

Laser Photonics has secured an order from a Costa Rican fabrication company for its CleanTech Laser Cleaning System. The deal is expected to boost the company's revenues and strengthen its position in the market.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:25 pm

XERS

Xeris Biopharma has revised its 2023 revenue guidance from a range of $155M-$165M to a narrower range of $160M-$165M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:22 pm

APYX

Apyx Medical has revised its FY23 revenue forecast to $53M-$54M, down from its previous guidance of $59M-$62M and consensus of $59.68M. This represents a growth of 19% to 21% compared to the total revenue of $44.5 million for the year ended December 31, 2022.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:21 pm

XTNT

Xtant Medical has increased its FY23 revenue guidance to $88M-$91M, up from the previous guidance of $75M-$77M and surpassing the consensus of $77.00M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:19 pm